Nuvectis Pharma annual r&d spending
2021
2022
2023
2024
2025
Nuvectis Pharma R&D Spending Growth & History (NVCT)
Nuvectis Pharma's r&d spending was $18.2M for fiscal 2025.
View full Nuvectis Pharma company overviewNuvectis Pharma annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $18.2M | $5.2M | +40.52% |
| 2024 | 2024-12-31 | $12.9M | −$2.5M | −16.01% |
| 2023 | 2023-12-31 | $15.4M | $2.2M | +16.28% |
| 2022 | 2022-12-31 | $13.2M | $3.7M | +38.58% |
| 2021 | 2021-12-31 | $9.5M | — | — |
Nuvectis Pharma quarterly r&d spending
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $4.7M | $1.1M | +29.64% |
| Q1 2026 | 2026-03-31 | $4.1M | $426,000 | +11.58% |
| Q4 2025 | 2025-12-31 | $5.1M | $590,000 | +13.12% |
| Q3 2025 | 2025-09-30 | $5.8M | $3.0M | +104.82% |
| Q2 2025 | 2025-06-30 | $3.6M | $670,000 | +22.77% |
| Q1 2025 | 2025-03-31 | $3.7M | $1.0M | +38.35% |
| Q4 2024 | 2024-12-31 | $4.5M | $231,000 | +5.42% |
| Q3 2024 | 2024-09-30 | $2.8M | −$1.7M | −37.16% |
| Q2 2024 | 2024-06-30 | $2.9M | −$1.3M | −30.95% |
| Q1 2024 | 2024-03-31 | $2.7M | $293,000 | +12.38% |
| Q4 2023 | 2023-12-31 | $4.3M | −$132,000 | −3.00% |
| Q3 2023 | 2023-09-30 | $4.5M | −$34,000 | −0.75% |
| Q2 2023 | 2023-06-30 | $4.3M | $1.8M | +70.14% |
| Q1 2023 | 2023-03-31 | $2.4M | $562,000 | +31.14% |
| Q4 2022 | 2022-12-31 | $4.4M | — | — |
| Q3 2022 | 2022-09-30 | $4.5M | $364,000 | +8.76% |
| Q2 2022 | 2022-06-30 | $2.5M | −$1.7M | −40.99% |
| Q1 2022 | 2022-03-31 | $1.8M | — | — |
| Q3 2021 | 2021-09-30 | $4.2M | — | — |
| Q2 2021 | 2021-06-30 | $4.2M | — | — |
Nuvectis Pharma r&d spending trends
Between the periods ended 2021-12-31 and 2025-12-31, Nuvectis Pharma's r&d spending increased from $9.5M to $18.2M, a change of $8.6M. The latest reported quarter, Q2 2026, shows $4.7M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nuvectis Pharma source filings ↗